Kames Capital Management’s Gilead Sciences GILD Stock Holding History

Kames Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$56M	Sell	593,591 -124,087	-17%	-$12.8M	1.65%	23
2014 Q3	$76.4M	Sell	717,678 -96,352	-12%	-$9.43M	2.39%	9
2014 Q2	$67.5M	Buy	814,030 +252,846	+45%	+$19.7M	2.15%	12
2014 Q1	$39.8M	Buy	561,184 +526,094	+1,499%	+$41.3M	1.26%	31
2013 Q4	$2.64M	Hold	35,090	–	–	0.09%	95
2013 Q3	$2.21M	Sell	35,090 -24,780	-41%	-$1.48M	0.07%	104
2013 Q2	$3.07M	Buy	+59,870	New	+$3.12M	0.11%	87

Other funds holding GILD

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Kames Capital Management's GILD Position: Q4 2014 in Review

Kames Capital Management reduced its Gilead Sciences (GILD) stake by 17% in Q4 2014, selling an estimated $12.8M and leaving 593,591 shares worth $56M. The position accounts for 1.65% of the portfolio, ranked #23.

Kames Capital Management first reported a position in GILD in Q2 2013 and has held it in 7 quarters since. The position peaked at $76.4M in Q3 2014. 1,438 funds tracked by Wall St. Rank hold GILD as of Q4 2014.

Kames Capital Management held 593,591 shares of Gilead Sciences worth $56M as of Q4 2014.
Kames Capital Management sold 124,087 Gilead Sciences shares in Q4 2014, an estimated $12.8M.
Gilead Sciences made up 1.65% of Kames Capital Management's portfolio in Q4 2014, its #23 holding.
Kames Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 7 quarters since.
Kames Capital Management's Gilead Sciences position peaked at $76.4M in Q3 2014.
1,438 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2014.

Based on Kames Capital Management's 13F filing for Q4 2014, filed 3 Feb 2015.